Disclosure Of Effect Of Changes In Foreign Exchange Rates [Text Block]

Xspray Pharma - Filing #679275

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Disclosure of effect of changes in foreign exchange rates [text block]	—	—	*	—	—	—	—	—	—	—	—	—	—	—
Disclosure of information when currency is not exchangeable into another currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of information when foreign operation’s functional currency is not exchangeable into presentation currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [abstract]
Disclosure of summarised financial information about foreign operation [line items]
Non-current assets	—	—	—	547 448 SEK	—	—	—	453 200 SEK	—	—	—	—	—	—
Current assets	—	—	—	217 815 SEK	—	—	—	132 229 SEK	—	—	—	—	—	—
Non-current liabilities	—	—	—	31 947 SEK	—	—	—	560,000 SEK	—	—	—	—	—	—
Current liabilities	—	—	—	39 903 SEK	—	—	—	28 851 SEK	—	—	—	—	—	—
Revenue	—	—	– SEK	—	—	—	—	—	—	—	– SEK	—	—	—
Profit (loss)	- SEK	- SEK	179 667 SEK	—	179 667 SEK	- SEK	—	—	– SEK	– SEK	131 670 SEK	131 670 SEK	- SEK	– SEK
Other comprehensive income	- SEK	- SEK	184,000 SEK	—	- SEK	- SEK	184,000 SEK	—	– SEK	– SEK	– SEK	– SEK	- SEK	– SEK
Comprehensive income	- SEK	- SEK	179 851 SEK	—	179 667 SEK	- SEK	184,000 SEK	—	– SEK	– SEK	131 670 SEK	131 670 SEK	- SEK	– SEK